Preferred Label : carbamates;
MeSH definition : Derivatives of carbamic acid, H2NC( O)OH. Included under this heading are N-substituted
and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes,
and polymers that include repeating units of carbamate are referred to as POLYURETHANES.
Note however that polyurethanes are derived from the polymerization of ISOCYANATES
and the singular term URETHANE refers to the ethyl ester of carbamic acid.;
MeSH synonym : Carbamate;
MeSH hyponym : carbamic acids; Acids, Carbamic; Aminoformic Acids; Acids, Aminoformic;
Wikipedia link : https://en.wikipedia.org/wiki/Carbamate;
Is substance : O;
Origin ID : D002219;
UMLS CUI : C0006948;
ATC code(s)
Allowable qualifiers
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- A 84538 [MeSH Supplementary Concept]
- AB-506 [MeSH Supplementary Concept]
- AQ 148 [MeSH Supplementary Concept]
- AS 115 [MeSH Supplementary Concept]
- AVN 944 [MeSH Supplementary Concept]
- BK 141 [MeSH Supplementary Concept]
- BL443 [MeSH Supplementary Concept]
- BO-1012 [MeSH Supplementary Concept]
- BPMC [MeSH Supplementary Concept]
- BR 383 [MeSH Supplementary Concept]
- BR 384 [MeSH Supplementary Concept]
- CGK012 [MeSH Supplementary Concept]
- CI 1021 [MeSH Supplementary Concept]
- COB223 [MeSH Supplementary Concept]
- Cbz-B3A [MeSH Supplementary Concept]
- D 19050 [MeSH Supplementary Concept]
- FK-788 [MeSH Supplementary Concept]
- FSC 231 [MeSH Supplementary Concept]
- GRL008 [MeSH Supplementary Concept]
- HS 37 [MeSH Supplementary Concept]
- IRA-938 [MeSH Supplementary Concept]
- IRE-6A [MeSH Supplementary Concept]
- IRE-7B [MeSH Supplementary Concept]
- JZL195 [MeSH Supplementary Concept]
- KI 328 [MeSH Supplementary Concept]
- KYT-36 [MeSH Supplementary Concept]
- LU 253 [MeSH Supplementary Concept]
- MJN110 [MeSH Supplementary Concept]
- NPI 2 [MeSH Supplementary Concept]
- P 10358 [MeSH Supplementary Concept]
- PL 100 [MeSH Supplementary Concept]
- RB 346 [MeSH Supplementary Concept]
- RO-5657 [MeSH Supplementary Concept]
- SH045 [MeSH Supplementary Concept]
- SV119 [MeSH Supplementary Concept]
- TMC 49A [MeSH Supplementary Concept]
- TX 1835 [MeSH Supplementary Concept]
- TX 1845 [MeSH Supplementary Concept]
- URB 532 [MeSH Supplementary Concept]
- antral [MeSH Supplementary Concept]
- apcin [MeSH Supplementary Concept]
- asulam [MeSH Supplementary Concept]
- barban [MeSH Supplementary Concept]
- betamix [MeSH Supplementary Concept]
- boletin [MeSH Supplementary Concept]
- indoxam [MeSH Supplementary Concept]
- isolan [MeSH Supplementary Concept]
- meobal [MeSH Supplementary Concept]
- oxamyl [MeSH Supplementary Concept]
- primor [MeSH Supplementary Concept]
- pularyl [MeSH Supplementary Concept]
- pyrolan [MeSH Supplementary Concept]
- tirpate [MeSH Supplementary Concept]
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
Derivatives of carbamic acid, H2NC( O)OH. Included under this heading are N-substituted
and O-substituted carbamic acids. In general carbamate esters are referred to as urethanes,
and polymers that include repeating units of carbamate are referred to as POLYURETHANES.
Note however that polyurethanes are derived from the polymerization of ISOCYANATES
and the singular term URETHANE refers to the ethyl ester of carbamic acid.
https://ansm.sante.fr/tableau-atu-rtu/ontozry-12-5-mg-comprime-ontozry-25-mg-comprime-pellicule-ontozry-50-mg-comprime-pellicule-ontozry-100-mg-comprime-pellicule-ontozry-150-mg-comprime-pellicule-ontozry-200-mg-comprime-pellicule
2022
false
false
false
France
French
guidelines for drug use
administration, oral
Cenobamate
Cenobamate
summary of product characteristics
package leaflet
adult
epilepsies, partial
anticonvulsants
anticonvulsants
Product containing only cenobamate in oral dose form (medicinal product form)
carbamates
chlorophenols
tetrazoles
carbamates
chlorophenols
tetrazoles
---
https://www.santepubliquefrance.fr/determinants-de-sante/exposition-a-des-substances-chimiques/pesticides/documents/enquetes-etudes/impregnation-de-la-population-francaise-par-les-carbamates.-programme-national-de-biosurveillance-esteban-2014-2016
2021
France
technical report
population
Biological Monitoring
Program
carbamates
biosurveillance
carbamates, nos
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
carbamates
carbamates
chlorophenols
chlorophenols
tetrazoles
tetrazoles
cenobamate
anticonvulsants
anticonvulsants
seizures
adult
drug therapy, combination
administration, oral
product surveillance, postmarketing
epilepsies, partial
aged
drug interactions
pregnancy
breast feeding
GABA modulators
drug evaluation, preclinical
Cenobamate
Cenobamate
---
https://www.has-sante.fr/jcms/p_3193178/fr/sunosi
2020
false
false
false
France
Solriamfetol
Solriamfetol
administration, oral
solriamfetol
insurance, health, reimbursement
phenylalanine
carbamates
adult
narcolepsy
Excessive daytime sleepiness
sleep apnea, obstructive
treatment outcome
evaluation of the transparency committee
solriamfetol
solriamfetol
---
https://ansm.sante.fr/tableau-atu-rtu/braftovi-75-mg-gelule
2020
false
false
false
France
French
drug information
encorafenib
encorafenib
administration, oral
Cetuximab
adult
antineoplastic combined chemotherapy protocols
BRAF V600E Mutation Present
neoplasm metastasis
colorectal neoplasms
Colorectal cancer metastatic
carbamates
sulfonamides
---
https://www.has-sante.fr/jcms/p_3224423/fr/epclusa
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
administration, oral
sofosbuvir-velpatasvir drug combination
antiviral agents
Product containing only sofosbuvir and velpatasvir in oral dose form (medicinal product
form)
sofosbuvir and velpatasvir
hepatitis C, chronic
adult
adolescent
child
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.has-sante.fr/jcms/p_3225446/fr/braftovi
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
encorafenib
encorafenib
administration, oral
adult
BRAF V600E Mutation Present
colorectal neoplasms
colorectal neoplasms
mutation
neoplasm metastasis
Colorectal cancer metastatic
proto-oncogene proteins b-raf
antineoplastic combined chemotherapy protocols
Cetuximab/Encorafenib Regimen
Cetuximab
antineoplastic agents
protein kinase inhibitors
proto-oncogene proteins b-raf
metastatic colorectal cancer with a BRAF V600E mutation
evaluation of the transparency committee
carbamates
sulfonamides
---
https://www.ema.europa.eu/en/medicines/human/EPAR/sunosi
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, oral
disorders of excessive somnolence
narcolepsy
sleep apnea, obstructive
solriamfetol
Solriamfetol
Solriamfetol
carbamates
carbamates
phenylalanine
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
solriamfetol
solriamfetol
---
https://www.has-sante.fr/jcms/p_3152667/fr/epclusa
2020
false
false
false
France
Sofosbuvir
velpatasvir
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
Epclusa
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
---
https://www.has-sante.fr/jcms/p_3152658/fr/vosevi
2020
false
false
false
France
sofosbuvir, velpatasvir and voxilaprevir
drug combinations
Sofosbuvir
velpatasvir
voxilaprevir
adult
administration, oral
treatment outcome
insurance, health, reimbursement
hepatitis C, chronic
antiviral agents
evaluation of the transparency committee
carbamates
Heterocyclic Compounds, 4 or More Rings
sulfonamides
macrocyclic compounds
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.has-sante.fr/jcms/p_3115175/fr/epclusa
2019
false
false
false
France
sofosbuvir and velpatasvir
hepatitis C, chronic
evaluation of the transparency committee
sofosbuvir-velpatasvir drug combination
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://www.has-sante.fr/jcms/p_3067182/fr/braftovi-mektovi
2019
false
true
false
false
France
French
antineoplastic combined chemotherapy protocols
encorafenib
binimetinib
administration, oral
protein kinase inhibitors
survival analysis
adult
insurance, health, reimbursement
melanoma
Unresectable Melanoma
BRAF V600 Mutation
proto-oncogene proteins b-raf
encorafenib
binimetinib
carbamates
sulfonamides
---
https://pharmacomedicale.org/medicaments/par-specialites/item/glinides
2018
false
true
false
France
hypoglycemic agents
repaglinide
diabetes mellitus, type 2
drug information
carbamates
piperidines
---
https://vigilanses.anses.fr/sites/default/files/VigilansesN6_Prosulfocarbe_1.pdf
2018
France
journal article
popular works
prosulfocarb
malus
carbamates
---
https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
encorafenib
encorafenib
drug approval
europe
treatment outcome
melanoma
melanoma
BRAF V600 Mutation
proto-oncogene proteins b-raf
mutation
antineoplastic combined chemotherapy protocols
administration, oral
product surveillance, postmarketing
adult
aged
drug interactions
pregnancy
breast feeding
raf kinases
protein kinase inhibitors
protein kinase inhibitors
Progression-Free survival
survival analysis
drug evaluation, preclinical
colorectal neoplasms
neoplasm metastasis
metastatic colorectal cancer with a BRAF V600E mutation
Binimetinib/Encorafenib Regimen
Cetuximab/Encorafenib Regimen
encorafenib
carbamates
sulfonamides
disease-free survival
carbamates
sulfonamides
carbamates
sulfonamides
---
https://www.has-sante.fr/portail/jcms/c_2775799/fr/viekirax-exviera
2017
false
false
false
false
France
French
evaluation of the transparency committee
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
carbamates
antiviral agents
macrocyclic compounds
ritonavir
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
ombitasvir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir
paritaprevir
---
https://www.has-sante.fr/portail/jcms/c_2817995/fr/vosevi
2017
false
false
false
France
French
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
treatment outcome
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
insurance, health, reimbursement
evaluation of the transparency committee
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
https://www.ema.europa.eu/medicines/human/EPAR/Vosevi
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
sulfonamides
sulfonamides
macrocyclic compounds
macrocyclic compounds
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug approval
europe
treatment outcome
product surveillance, postmarketing
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
adult
drug interactions
pregnancy
breast feeding
NS-5 protein, hepatitis C virus
NS-5a protein, hepatitis C virus
Substance with Hepatitis C virus NS3/4A protease inhibitor mechanism of action (substance)
viral nonstructural proteins
serine proteases
drug evaluation, preclinical
sofosbuvir, velpatasvir and voxilaprevir
voxilaprevir
voxilaprevir
NS3-4A serine protease, Hepatitis C virus
Sofosbuvir
velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
sofosbuvir velpatasvir voxilaprevir drug combination
---
http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=42484
http://circulaire.legifrance.gouv.fr/pdf/2017/08/cir_42484.pdf
2017
false
false
false
France
French
legislation
insurance, health, reimbursement
hepatitis C, chronic
elbasvir-grazoprevir drug combination
dasabuvir
legislation, drug
antiviral agents
ritonavir
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
ombitasvir
paritaprevir
direct acting antivirals
daclatasvir
administration, oral
Simeprevir
sofosbuvir-velpatasvir drug combination
ledipasvir, sofosbuvir drug combination
Multidisciplinary care conference (procedure)
Interdisciplinary medical team conference (procedure)
dasabuvir
ombitasvir
paritaprevir
daclatasvir
benzofurans
drug combinations
imidazoles
quinoxalines
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
sulfonamides
uracil
uracil
anilides
macrocyclic compounds
---
http://www.has-sante.fr/portail/jcms/c_2630025/fr/repaglinide-arrow-lab
2016
false
false
false
France
French
evaluation of the transparency committee
drugs, generic
repaglinide
carbamates
piperidines
---
https://www.ema.europa.eu/medicines/human/EPAR/Epclusa
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
velpatasvir
velpatasvir
drug combinations
Sofosbuvir
Sofosbuvir
antiviral agents
antiviral agents
pregnancy
breast feeding
drug interactions
hepatitis C, chronic
adult
administration, oral
drug therapy, combination
NS-5a protein, hepatitis C virus
enzyme inhibitors
enzyme inhibitors
RNA-Dependent RNA Polymerase
product surveillance, postmarketing
aged
drug evaluation, preclinical
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
NS-5 protein, hepatitis C virus
viral nonstructural proteins
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
Sofosbuvir
carbamates
Heterocyclic Compounds, 4 or More Rings
---
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa
http://www.has-sante.fr/portail/jcms/c_2724396/fr/epclusa-sofosbuvir/velpatasvir-association-fixe-d-antiviraux-a-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
drug combinations
Sofosbuvir
Sofosbuvir
administration, oral
hepatitis C, chronic
antiviral agents
antiviral agents
velpatasvir
velpatasvir
hepatitis C, chronic
adult
guidelines for drug use
sofosbuvir-velpatasvir drug combination
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
carbamates
Heterocyclic Compounds, 4 or More Rings
carbamates
Heterocyclic Compounds, 4 or More Rings
drug combinations
drug combinations
---
http://www.has-sante.fr/portail/jcms/c_2633680/fr/antiviraux-d-action-directe
2016
false
false
false
France
French
evaluation of the transparency committee
adult
hepatitis C, chronic
drug therapy, combination
Sofosbuvir
antiviral agents
direct acting antivirals
daclatasvir
Simeprevir
ledipasvir, sofosbuvir drug combination
dasabuvir
drug combinations
ombitasvir
ritonavir
paritaprevir
fibrosis, liver
risk
has patient
hepacivirus
Infections
autoimmune diseases
hepatic fibrosis, nos
fibrosis
hepatitis C virus
human enterovirus 72
hepatitis C, chronic
business
liver cirrhosis
socialism
patients
chronic infectious disease
guideline
antiviral agents
chronic hepatitis, nos
health
case management
hepatitis c virus
hepatitis a virus
dasabuvir
ombitasvir
paritaprevir
daclatasvir
fibrosis
commerce
patients
guideline
benzimidazoles
fluorenes
uridine monophosphate
sulfonamides
uracil
uracil
anilides
carbamates
macrocyclic compounds
imidazoles
---
http://www.has-sante.fr/portail/jcms/c_2728866/fr/reevaluation-des-antiviraux-d-action-directe-dans-le-traitement-de-l-hepatite-c
2016
false
false
false
France
French
guidelines for drug use
practice guideline
antiviral agents
hepatitis C, chronic
drug evaluation
Sofosbuvir
administration, oral
Simeprevir
direct acting antivirals
daclatasvir
ledipasvir
ledipasvir, sofosbuvir drug combination
drug therapy, combination
ritonavir
ombitasvir
paritaprevir
dasabuvir
drug resistance, viral
drug interactions
treatment outcome
daclatasvir
ombitasvir
paritaprevir
dasabuvir
benzimidazoles
fluorenes
uridine monophosphate
uridine monophosphate
imidazoles
anilides
carbamates
macrocyclic compounds
sulfonamides
uracil
uracil
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00329
2016
false
false
false
Canada
French
drug information
sofosbuvir-velpatasvir drug combination
sofosbuvir and velpatasvir
Sofosbuvir
carbamates
drug combinations
Heterocyclic Compounds, 4 or More Rings
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00250
2015
false
false
false
Canada
French
English
drug information
Product containing ombitasvir and paritaprevir and ritonavir in oral dose form (medicinal
product form)
drug combinations
ritonavir
paritaprevir
ombitasvir
ombitasvir, paritaprevir and ritonavir
paritaprevir
ombitasvir
macrocyclic compounds
anilides
carbamates
---
Viekirax - ombitasvir / paritaprevir / ritonavir
https://www.ema.europa.eu/medicines/human/EPAR/Viekirax
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
anilides
anilides
drug approval
europe
carbamates
carbamates
hepatitis C, chronic
drug therapy, combination
antiviral agents
antiviral agents
macrocyclic compounds
macrocyclic compounds
ritonavir
ritonavir
administration, oral
cytochrome p-450 cyp3a
NS-5 protein, hepatitis C virus
NS4A cofactor peptide, hepatitis C virus
NS3 protein, hepatitis C virus
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ombitasvir
ombitasvir
paritaprevir
paritaprevir
paritaprevir
paritaprevir
ombitasvir, paritaprevir and ritonavir
viral nonstructural proteins
carrier proteins
viral nonstructural proteins
ombitasvir
ombitasvir
---
http://www.has-sante.fr/portail/jcms/c_2025737/fr/exviera/viekirax
http://www.has-sante.fr/portail/jcms/c_2025737/fr/viekirax-ombitasvir/paritaprevir/ritonavir-association-fixe-dantiviraux-a-action-directe-exviera-dasabuvir-antiviral-a-action-directe
2015
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
drug combinations
administration, oral
hepatitis C, chronic
drug therapy, combination
adult
anilides
anilides
carbamates
carbamates
antiviral agents
antiviral agents
macrocyclic compounds
macrocyclic compounds
ritonavir
ritonavir
sulfonamides
sulfonamides
uracil
treatment outcome
insurance, health, reimbursement
Hepatitis C virus genotype 1 (organism)
Hepatitis C virus genotype 4 (organism)
ombitasvir
paritaprevir
dasabuvir
paritaprevir
dasabuvir
ombitasvir, paritaprevir and ritonavir
ombitasvir
dasabuvir
---
Gluconorm (repaglinide) - New Contraindication for Concomitant Use with Clopidogrel
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/54454a-fra.php
2015
false
false
false
Canada
French
English
drug interactions
repaglinide
repaglinide
clopidogrel
diabetes mellitus, type 2
hypoglycemic agents
purinergic P2Y receptor antagonists
platelet aggregation inhibitors
hypoglycemia
pharmacovigilance note
Cytochrome P-450 CYP2C8 Inhibitors
carbamates
piperidines
Contraindications, Drug
Clopidogrel
---
Information Update - Risk of Serious Liver Injury associated with Hepatitis C Treatments:
Holkira Pak and Technivie
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/55800a-fra.php
2015
false
false
false
Canada
French
English
Chemical and Drug Induced Liver Injury
pharmacovigilance note
antiviral agents
hepatitis C, chronic
drug combinations
antiviral agents
ombitasvir
paritaprevir
ritonavir
dasabuvir
ombitasvir
dasabuvir
anilides
carbamates
sulfonamides
uracil
uracil
macrocyclic compounds
Contraindications, Drug
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=872192&nom=Carbamate+de+bêta-hydroxyéthyle
Canada
toxicological data sheet
carbamates
---
https://www.ema.europa.eu/medicines/human/EPAR/Prandin
2012
United Kingdom
French
English
syndication feed
hypoglycemic agents
carbamates
diabetes mellitus, type 2
piperidines
drug interactions
carbamates
piperidines
hypoglycemic agents
treatment outcome
drug evaluation
drug labeling
drug approval
tablets
administration, oral
drug therapy, combination
pregnancy
breast feeding
repaglinide
repaglinide
repaglinide
carbamates
piperidines
summary of product characteristics
package leaflet
drug evaluation
---
https://www.ema.europa.eu/medicines/human/EPAR/Novonorm
2012
United Kingdom
English
French
syndication feed
carbamates
piperidines
hypoglycemic agents
carbamates
piperidines
hypoglycemic agents
drug interactions
treatment outcome
drug evaluation
pregnancy
drug approval
drug labeling
tablets
administration, oral
drug therapy, combination
breast feeding
diabetes mellitus, type 2
repaglinide
repaglinide
repaglinide
carbamates
piperidines
summary of product characteristics
drug evaluation
package leaflet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=116434&nom=Chlorure+de+di%E9thylcarbamyle++
Canada
French
carbamates
diethylcarbamoyl chloride
toxicological data sheet
---
http://www.inrs.fr/accueil/produits/bdd/doc/fichetox.html?refINRS=FT%20214
France
French
benzimidazoles
benzimidazoles
carbamates
carbamates
benzimidazoles
benzimidazoles
benzimidazoles
carbamates
carbamates
carbamates
occupational exposure
occupational diseases
reference values
carbendazim
guidelines
toxicological data sheet
---
https://reptox.cnesst.gouv.qc.ca/pages/fiche-complete.aspx?no_produit=112375&nom=Chlorure+de+dim%E9thyl+carbamoyle
Canada
French
carbamates
dimethylcarbamyl chloride
toxicological data sheet
---
https://www.ema.europa.eu/medicines/human/EPAR/Agenerase
2011
false
United Kingdom
English
French
syndication feed
Contraindications, Procedure
sulfonamides
sulfonamides
sulfonamides
anti-hiv agents
anti-hiv agents
anti-hiv agents
anti-hiv agents
anti-hiv agents
anti-hiv agents
hiv protease inhibitors
hiv protease inhibitors
hiv protease inhibitors
hiv protease inhibitors
hiv protease inhibitors
hiv protease inhibitors
amprenavir
child
anti-hiv agents
hiv infections
HIV-1
hiv protease inhibitors
treatment outcome
drug evaluation
pregnancy
breast feeding
drug labeling
drug approval
drug evaluation, preclinical
administration, oral
sulfonamides
capsules
carbamates
adult
carbamates
carbamates
carbamates
carbamates
drug interactions
carbamates
drug resistance, viral
carbamates
sulfonamides
sulfonamides
sulfonamides
amprenavir
carbamates
sulfonamides
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug
---
https://www.ema.europa.eu/medicines/human/EPAR/Telzir
2011
United Kingdom
French
English
syndication feed
Contraindications, Procedure
hiv infections
acquired immunodeficiency syndrome
organophosphates
carbamates
anti-hiv agents
adult
HIV-1
drug therapy, combination
hiv protease inhibitors
drug evaluation
treatment outcome
organophosphates
organophosphates
carbamates
carbamates
drug interactions
anti-hiv agents
anti-hiv agents
hiv protease inhibitors
hiv protease inhibitors
sulfonamides
sulfonamides
sulfonamides
sulfonamides
tablets
pharmaceutical solutions
administration, oral
organophosphates
carbamates
anti-hiv agents
hiv protease inhibitors
child
adolescent
anti-hiv agents
anti-hiv agents
hiv protease inhibitors
hiv protease inhibitors
organophosphates
organophosphates
carbamates
carbamates
sulfonamides
sulfonamides
pregnancy
breast feeding
drug evaluation, preclinical
sulfonamides
organophosphates
carbamates
anti-hiv agents
hiv protease inhibitors
drug labeling
drug approval
fosamprenavir
fosamprenavir
carbamates
organophosphates
sulfonamides
drug evaluation
package leaflet
summary of product characteristics
Contraindications, Drug
---
http://www.meddispar.fr/medicaments/3640639
2008
France
French
fosamprenavir
organophosphates
sulfonamides
drug prescriptions
legislation, drug
carbamates
tablets
administration, oral
fosamprenavir
drug information
---